# US 2016/0250290 A1 · Gene therapy for diabetic ischemic disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0250290 A1
- Document ID: US20160250290A1
- Status: Published application
- Kind: A1
- Application number: 14/867,866
- Filed: 2015-09-28
- Published: 2016-09-01
- Earliest claimed: 1999-10-29
- Assignees: AnGes MG, Inc.
- Applicants: AnGes MG, Inc.
- Inventors: Ryuichi Morishita; Toshio Ogihara
- Web page: https://patentgrep.com/patent/US20160250290A1

## CPC

- A61K 38/1833: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 48/0016: {wherein the nucleic acid is delivered as a 'naked' nucleic acid, i.e. not combined with an entity such as a cationic lipid}
- A61K 48/0025: {wherein the non-active part clearly interacts with the delivered nucleic acid}
- A61K 48/0075: {characterised by an aspect of the delivery route, e.g. oral, subcutaneous}
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C07K 14/4753: {Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II}
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2760/18843: viral genome or elements thereof as genetic vector
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

It is possible to stimulate the angiogenesis of an ischemic site declined by diabetes and to recuperate ischemic disease by administering HGF (hepatocyte growth factor) gene to the diabetic ischemic.

## Claims

### Claim 1

A method for the treatment of diabetic ischemic disease in a subject, comprising nonivasively administering a therapeutically effective amount of a hepatocyte growth factor (HGF) gene directly to a muscle of an ischemic site, and measuring blood flow, wherein expression of the HGF gene increases blood flow in the diabetic subject compared to the blood flow of an HGF-treated non-diabetic subject with ischemic disease, thereby treating the diabetic ischemic disease.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the HGF gene is in the form of a Sendai virus (HVJ)-liposome.

### Claim 3 (depends on 1)

The method according to claim 1, wherein about 50 μg to about 5 mg the HGF gene is administered to the subject, thereby treating the diabetic ischemic disease.

### Claim 4 (depends on 1)

The method of claim 1, wherein the HGF gene is administered as a naked DNA.

### Claim 5 (depends on 1)

The method of claim 1, wherein the HGF gene is administered as a naked expression vector DNA.

### Claim 6 (depends on 1)

The method of claim 1, wherein administration of the HGF gene increases blood flow compared to the blood flow following administration of an HGF-recombinant protein.

### Claim 7 (depends on 1)

The method of claim 1, wherein the diabetic ischemic disease is selected from the group consisting of diabetic lower limb ischemic disease, diabetic ischemic neuropathy, and diabetic ischemic myocardial infarction.

### Claim 8 (depends on 7)

The method of claim 7, wherein the diabetic ischemic disease is diabetic lower limb ischemic disease.
